Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > ORGANIZATION
ORGANIZATION
- JPA to Bolster Strategies for Key Issues thru Policy Study Committee: Pres. Kodama
July 2, 2013
- JMA Sets Up Pharmaceutical Affairs Section
July 1, 2013
- Generic Share Reaches 25.8% by Volume, 10.5% by Price in FY2012: JGA
July 1, 2013
- JGA to Establish New Membership Category to Encourage Non-Member Companies to Provide Information through Its Website
June 27, 2013
- JGA Concerned about TPP Talks, Hopes Japan Will Adopt US Rules Favorable to Generic Makers
June 24, 2013
- JPMA Weighs Scheme to Allow Use of Clinical Research Evidence for Drug Applications
June 21, 2013
- Generic-Only Distributors Total 485, Only 17% Are Member Companies: Generic Distributor Association Survey
June 13, 2013
- FPMAJ Subcommittee Floats New Pricing Rule to Replace Cost Calculation Method
June 12, 2013
- FPMAJ Subcommittee Says NHI Prices of Essential Drugs Should Be Maintained; Stable Supply System for Disasters Envisioned as Requirement
June 11, 2013
- 30% of Newly Listed Drugs in FY2012 Developed at Request of Govt: FPMAJ Survey
June 10, 2013
- FPMAJ Committee Appoints Eisai’s Tsuchiya, Takeda’s Aoyagi as Vice Chairman
June 7, 2013
- Consumers Need to Take Caution with Online OTC Drug Sales: Keizai Doyukai Chairman Hasegawa
June 7, 2013
- Lifting of Ban on Online OTC Drug Sales Would “Create Situation of Grave Concern”: JMA Vice President Nakagawa
June 7, 2013
- Pros and Cons of Bungyo Should Be Reconsidered: JMARI Working Paper
June 6, 2013
- Sawai Gains Steady Market Shares of Generics in Broad Categories, Meiji Seika Pharma Strong in CNS: Survey
June 4, 2013
- ACCJ, EBC Advocate Preventive Health, Say Physicians Should Earn More by Keeping People Out of Hospitals
June 3, 2013
- Fewer Drug Makers Used Outside Organizations for MR Education and Training in FY2012: MREAC
June 3, 2013
- Drug Makers, R&D Organizations Sign Memorandum to Search Compounds for Infectious Disease Treatment: GHIT Fund
June 3, 2013
- JMA Demands Novartis Disclose Details of Internal Probe
May 31, 2013
- Actions Taken in 29 Prefectures to Eliminate Free Benefits and Labor Provided by Wholesalers: Industry FTC Reports
May 29, 2013
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…